PMD PARTNERS WITH WELSH HOSPITAL TO ADVANCE RESEARCH ON BENEFITS THAT CONTINUOUS RESPIRATORY RATE MONITORING HAS WITH EXISTING SYSTEMS TO IMPROVE OUTCOMES
PMD advances research with Ysbyty Gwynedd Hospital, Bangor in Wales on the benefits that continuous respiratory rate monitoring has with existing systems to improve outcomes.
RespiraSense is a novel technology that provides continuous and accurate respiratory rate monitoring to alert medical staff to abnormal breathing, one of the earliest signs of possible patient deterioration from conditions such as respiratory compromise, worsening pneumonia, increasing severity of sepsis, and oncoming heart attacks.
“Respiratory rate is the best predictor of deterioration and the one that is measured the worst. We are looking forward to working with PMD to build safer systems for the care of patients.” -Dr Christian P. Subbe Consultant in Acute, Respiratory and Intensive Care Medicine Ysbyty Gwynedd, Bangor, Wales.
Myles Murray CEO of PMD stated, “The value of vital signs as prognostic indicators of patient outcome has been well established, while respiratory rate remains to be recognised as the earliest and most sensitive indicator of patient deterioration from conditions such as Sepsis and COPD associated Respiratory Compromise.”
“PMD’s novel platform technology will provide clinicians important and timely trending information to help prevent in-hospital adverse events. This technology supports global (Early Warning Score) initiatives while also providing a boost towards the implementation of digital (and paperless) healthcare. Adopting a systems approach to the implementation of this technology is essential for improving the early detection of respiratory compromise.”
“RespiraSense is establishing centres of excellence across Europe with world leading opinion leaders in the field of vital signs and patient deterioration. With the increasing pressures put onto healthcare institutions, prevention is the word when it comes to addressing both financial savings without compromising patient safety.”
“We look forward with confidence to our ongoing clinical investigations within emergency, perioperative and acute medicine settings. All demonstrating that a positive impact to both outcomes and financial savings is a reality.”
– Myles Murray-